Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.6247
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 98087853600.0
- FreeCF/Share 7.1636
- PFCF 6.7285
- PE 19.423
- Debt/Assets 0.5379
- DivYield 0.051
- ROE 0.2957
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J.
Read More
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Read More
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with patient investors well rewarded with rich dividend yields, pending growth acceleration.
Read More
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding, but heavy reliance on Eliquis and Opdivo, both facing patent expiries, clouds the outlook. Key upcoming data catalysts and a new CMO offer hope, yet recent drug launches and acquisitions have underperformed expectations.
Read More
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointment, though early signs of the performance of acquired treatment Cobenfy are positive. Underwhelming earnings since last year, along with revenues that are still coming back in form could explain the loss of price momentum for BMY despite otherwise healthy stock metrics.
Read More
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
Read More
PCE Comes in Warmer Than Expected
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
PCE Comes in Warmer Than Expected.
Read More
Economy Heating Up on PCE for June
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
Read More
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Published: July 30, 2025 by: Forbes
Sentiment: Neutral
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements can provide valuable insights.
Read More
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Read More
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Read More
Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review.
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Published: July 17, 2025 by: CNBC
Sentiment: Neutral
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read More
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Published: July 17, 2025 by: Reuters
Sentiment: Positive
US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Read More
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
Read More
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
Published: July 17, 2025 by: WSJ
Sentiment: Positive
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Read More
Will Increased Expenses Affect Bristol Myers' Performance?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
Read More
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
Published: July 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
Read More
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Read More
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100